Salute e Benessere

Hyaluronic Acid Based Dermal Fillers Market Poised for Remarkable Growth Driven…

For a detailed analysis of Industry Trends And Growth Drivers, Explore The Full Hyaluronic Acid Based Dermal Fillers Market. For a detailed analysis of Industry Trends And Growth Drivers, Explore The Full Hyaluronic Acid Based Dermal Fillers Market . Browse in-depth TOC 202 - Pages126 – Tables 37 – Figures Global Hyaluronic Acid Based Dermal Fillers Market Overview Market Driver 1. Rising Demand for Non-Surgical Aesthetic ProceduresThe increasing...
PR Newswire
12/11/2025

Dental Chairs Market to Reach $820.84 Million by 2027 in the short run and…

Request Sample of the Report on Dental Chairs Market Forecast 2034 – https://www.alliedmarketresearch.com/request-sample/2658 Request Sample of the Report on Dental Chairs Market Forecast 2034 –https://www.alliedmarketresearch.com/request-sample/2658 Market Introduction A dental chair is a specialized medical device designed to position patients ergonomically during dental procedures while ensuring optimal access for practitioners. These chairs feature adjustable headrests,...
PR Newswire
12/11/2025

Life Science Instrumentation Market worth $92.5 billion by 2031 with 6.5% CAGR |…

Browse in-depth TOC on "Life Science Instrumentation Market" Browse in-depth TOC on "Life Science Instrumentation Market" 300 - Tables 50 - Figures 400 - Pages By technology,the life science instrumentation market is segmented into spectroscopy, chromatography, polymerase chain reaction (quantitative PCR, digital PCR), immunoassays, lyophilization, liquid handling systems, clinical chemistry analyzers, microscopy, flow cytometry, next-generation sequencing, centrifuges,...
PR Newswire
12/11/2025

Fragrance Diffuser Market to Reach $55.1 billion, Globally, by 2034 at 6.7%…

Download Sample Pages of Research Overview:https://www.alliedmarketresearch.com/request-sample/A299175 Download Sample Pages of Research Overview:https://www.alliedmarketresearch.com/request-sample/A299175 Prime determinants of growth The demand for fragrance diffuser has increased as more consumers prioritize holistic well-being and seek natural ways to improve their mental and physical health. Aromatherapy, which uses essential oils to promote relaxation, reduce stress, and...
PR Newswire
12/11/2025

AtomVie Global Radiopharma Supplies the First Patient Dose of 225Ac-SSO110 for…

"We are honored to partner with Ariceum to deliver the critical supply of 225Ac-SSO110 for the SANTANA-225 clinical trial. Our mission of transforming patients' lives with high quality radiopharmaceuticals drives every step of our work, and we are proud to contribute to bringing promising therapies in oncology closer to patients." said Bruno Paquin, CEO of AtomVie. "We are honored to partner with Ariceum to deliver the critical supply of 225Ac-SSO110 for the SANTANA-225 clinical…
PR Newswire
12/11/2025

/C O R R E C T I O N -- EirGenix, Inc./

EG1206A has completed its pharmacokinetic (PK) clinical study, and last month received positive feedback from both the U.S. FDA and the European Medicines Agency (EMA), confirming that the product qualifies for an abbreviated development pathway, allowing for the waiver of Phase III comparative efficacy trials. This agreement marks another major milestone and breakthrough in EirGenix's biosimilar development efforts. This partnership further strengthens the existing collaboration between Sandoz…
PR Newswire
12/11/2025

Chiesi Group Enters into an Exclusive License Agreement with Aliada…

“This agreement underscores our continued commitment to creating potential solutions that target the significant unmet needs in managing cognitive and neurological symptoms across several rare diseases,”Giacomo Chiesi, Executive Vice President,Chiesi Global Rare Diseases. “These aspects of the disease are frequently underserved, yet they can profoundly affect patients and their families. By advancing this research, we intend to go beyond symptom management and potentially address the...
Nasdaq GlobeNewswire
12/11/2025

Keralty and Total Care Saudi (TCS) Form Strategic Alliance to Advance Population…

The alliance seeks to shift the focus of healthcare from reactive disease management to predictive and proactive health management, guiding the evolution of TCS's successful Third-Party Administrator (TPA) model into a next-generation Population Health Services Organization (PHSO). This transformation will center on the comprehensive, integrated care of populations before they require high-cost interventions, enabling smarter use of resources and better health outcomes. The alliance seeks to...
PR Newswire
12/11/2025

Cypherpunk Technologies (formerly Leap Therapeutics) Reports Third Quarter 2025…

"This past month has been transformative for the Company, marked by closing a $58.88 million private placement led by Winklevoss Capital and successfully deploying $50 million to build a digital asset treasury designed to create long-term shareholder value focused on active participation in the development of Zcash and acquiring ZEC," said Douglas E. Onsi, President and CEO of Cypherpunk Technologies. "In our drug development business, we presented the final data from our…
PR Newswire
12/11/2025

Theriva™ Biologics Reports Third Quarter 2025 Operational Highlights and…

- Expanded data for VCN-01 (zabilugene almadenorepvec) in metastatic pancreatic ductal adenocarcinoma (PDAC) from the VIRAGE Phase 2b trial presented at the European Society for Medical Oncology (ESMO) Annual Congress 2025 -- Next generation oncolytic virus VCN-12 preclinical data presented at the 32 ndAnnual Congress European Society of Gene & Cell Therapy (ESGCT) -- Cash and cash equivalents of $7.5 millon as of September 30, 2025; recent capital raises increase cash to $15...
Nasdaq GlobeNewswire
12/11/2025

Evaxion announce 2026 financial calendar

/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, announces its financial calendar for 2026 as summarized below: March 5, 2026 : Business update and full year 2025 financial results April 16, 2026 : Annual General Meeting May 7, 2026 : Business update and first quarter 2026 financial results August 20, 2026 : Business update and second quarter 2026 financial results November 19, 2026 : Business update and third...
Nasdaq GlobeNewswire
12/11/2025

Alkermes Announces Positive Topline Results From Vibrance-2 Phase 2 Study of…

– Alixorexton Was Generally Well Tolerated at All Doses Tested – – Alixorexton Was Generally Well Tolerated at All Doses Tested – – Company to Host Investor Webcast onWednesday, Nov. 12at8:30 a.m. ET– DUBLIN , Nov. 12, 2025 /PRNewswire/ --Alkermes plc(Nasdaq: ALKS) today announced positive topline results from the Vibrance-2 dose-ranging phase 2 study evaluating alixorexton in patients with narcolepsy type 2 (NT2). Alixorexton, formerly referred to as ALKS 2680, is...
PR Newswire
12/11/2025

Genesis Automation Healthcare Announces Strategic Investment from Diversis…

The investment will accelerate Genesis's expansion across the United States, United Kingdom, and Ireland and advance the development of AI-powered analytics and predictive capabilities. Genesis's enhanced platform will address critical challenges in waste reduction, compliance, and clinical efficiency that healthcare organizations face worldwide. The investment will accelerate Genesis's expansion acrossthe United States,United Kingdom, andIrelandand advance the development of...
PR Newswire
12/11/2025

Immatics Achieves Clinical Proof-of-Concept of its Next-Generation TCR…

Company to hostconference call and webcasttoday, November 12, at 8:30 am EST/2:30 pm CETIMA402 and IMA401 TCR Bispecifics showed favorable tolerability at RP2D as well as deep and durable responses in heavily pre-treated, last-line patients with a range of solid tumors IMA402 PRAME Bispecific at RP2D range resulted in a 30% cORR (6/20) across all indications, including 29% (4/14) in melanoma and 2/3 confirmed responses in ovarian carcinoma IMA401 MAGEA4/8 Bispecific at ≥1...
Nasdaq GlobeNewswire
12/11/2025

Inside information: Bioretec initiates change negotiations to enhance…

The change negotiations will commence on 19 November 2025 and will last for an estimated 2 weeks. The change negotiations will commence on19 November 2025and will last for an estimated 2 weeks. A total of 15 employees from Bioretec's staff inFinlandare included in the scope of the negotiations. The negotiations may impact the employment terms of up to eight individuals. Topics under change negotiations include potential termination of employment, unilateral changes to employment...
PR Newswire
12/11/2025

EirGenix Signed The Commercial Licensinse Agreement for It's Second HER2…

Globally, there are approximately 2.3 million breast cancer patients, of which about 20% are diagnosed with HER2-positive disease. The Trastuzumab and Pertuzumab combination therapy has become the current standard of care for these patients. Recent studies also suggest that Pertuzumab combined with Trastuzumab deruxtecan (Enhertu®) may become the new first-line treatment for HER2-positive metastatic breast cancer, indicating strong potential for future market expansion of EG1206A. In addition to…
PR Newswire
12/11/2025

Swastik Wellbeing Sanctuary, India Honoured with the Global Emergence Wellness…

The award was presented by Ms. Uma Kumaran, Member of Parliament, United Kingdom, during a ceremony hosted by Crescent Meditours (UK) Ltd. The recognition highlights Swastik Wellbeing's global commitment to reimagining wellness as a multidimensional pursuit that unites traditional Indian healing sciences with modern therapeutic innovations. The award was presented by Ms. Uma Kumaran, Member of Parliament,United Kingdom, during a ceremony hosted by Crescent Meditours (UK) Ltd. The recognition...
PR Newswire
12/11/2025

New Study Uncovers Key Advances in Skin Longevity Research

Oripeptide-3 combines three purified peptides to boost cell energy, antioxidant protection and collagen production. It increases cell energy, reduces DNA and protein damage, and reactivates skin's defences, improving firmness, elasticity and wrinkles. Oripeptide-3 combines three purified peptides to boost cell energy, antioxidant protection and collagen production. It increases cell energy, reduces DNA and protein damage, and reactivates skin's defences, improving firmness, elasticity and ...
PR Newswire
12/11/2025

Millennials at highest risk of missing crucial cervical cancer screenings, finds…

"Millennials are often said to be the 'have it all generation,' juggling careers, caregiving, and societal expectations. Yet, they tend to put themselves last," said Joanna Sickler, Vice-President, Health Policy and External Affairs at Roche Diagnostics. "The research shows that millennials are disproportionately failing to prioritise cervical screening, because of a mix of emotional, logistical, and societal pressures. It's critical to design solutions like self-sampling that…
PR Newswire
12/11/2025

DBV Technologies Announces Last Patient Visit Completed in VITESSE Phase 3…

DBV Technologies Announces Last Patient Visit Completed in VITESSE Phase 3 Clinical Trial of VIASKIN ®Peanut Patch in Peanut Allergic Children Aged 4-7 YearsCompany remains on track for VITESSE topline data in Q4 of this year DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT – CUSIP: 23306J309), a clinical-stage biopharmaceutical company, today announced that the last patient visit has been completed in the Company’s Phase 3 VITESSE clinical...
Nasdaq GlobeNewswire
12/11/2025

Centessa Pharmaceuticals Announces Pricing of $250,000,000 Public Offering of…

BOSTON and LONDON, Nov.11, 2025(GLOBE NEWSWIRE) --Centessa Pharmaceuticals plc(Nasdaq: CNTA), a clinical-stage pharmaceutical company, today announced the pricing of an underwritten public offering of 11,627,907 American Depositary Shares (“ADSs”), each representing one ordinary share, at a price to the public of $21.50 per ADS. The aggregate gross proceeds to Centessa from this offering are expected to be approximately $250 million, before deducting underwriting discounts and...
Nasdaq GlobeNewswire
12/11/2025

Antibody-Mediated Rejection Market Set to Expand Significantly During the…

Antibody-mediated Rejection Market Summary Antibody-mediated Rejection Market Summary Discover the antibody-mediated rejection new treatment @New Treatments for Antibody-mediated Rejection Key Factors Driving the Growth of the Antibody-mediated Rejection Market Rising Number of Transplants and Transplant Candidates The rising number of organ transplants has driven a parallel increase in AMR cases, highlighting the need for better diagnostics, closer monitoring, and...
PR Newswire
11/11/2025

NANOBIOTIX to Participate in Jefferies London Healthcare Conference

PARIS and CAMBRIDGE, Mass., Nov.11, 2025(GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO - NASDAQ: NBTX - the “ Company ”), a late-clinical stage biotechnology company pioneering nanotherapeutic approaches to expand treatment possibilities for patients with cancer and other major diseases, announced today that Company management will participate in a fireside chat at the following conference: Jefferies London Healthcare ConferenceDate: Monday, November 17, 2025 Time: 3pm GMT / 10am...
Nasdaq GlobeNewswire
11/11/2025

Centessa Pharmaceuticals Announces Proposed Public Offering of American…

BOSTON and LONDON, Nov.11, 2025(GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company, today announced that it has commenced an underwritten public offering of American Depositary Shares (“ADSs”), each representing one ordinary share. All of the ADSs are being offered by Centessa. In addition, Centessa intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the ADSs offered in the public offering. The...
Nasdaq GlobeNewswire
11/11/2025
Altri  Comunicati